Literature DB >> 14973052

Spontaneous vitiligo in an animal model for human melanoma: role of tumor-specific CD8+ T cells.

Renée Lengagne1, Frédérique-Anne Le Gal, Marylène Garcette, Laurence Fiette, Patrick Ave, Masashi Kato, Jean-Paul Briand, Christian Massot, Izumi Nakashima, Laurent Rénia, Jean-Gérard Guillet, Armelle Prévost-Blondel.   

Abstract

Tumor antigen-reactive T cells can be detected in a large proportion of melanoma patients, but their efficacy on tumor control in vivo remains unclear. On the other hand, vitiligo, a skin disorder characterized by patchy depigmented macules, may occur spontaneously or after antitumor therapies. Moreover, vitiligo is significantly associated with positive clinical response, but the mechanism is not understood. Therefore, the establishment of a relevant animal model in which melanoma and vitiligo spontaneously develop stepwise may be useful for better understanding of the parameters involved in the destruction of both benign and malignant melanocytes. In a previous work, we established a mouse model for melanoma in which MT/ret transgenic mice express the ret oncogene fused to the metallothionein promoter. Here we report that melanoma leads to spontaneous vitiligo. We further investigate, for the first time in this model, the natural antitumor T-cell response and evaluate the role of cellular immunity in the development of the disease. Interestingly, the occurrence of spontaneous tumor nodules in MT/ret mice with melanoma-associated vitiligo is significantly delayed when compared in melanoma mice without vitiligo. Moreover, a significant proportion of mice with melanoma-associated vitiligo resisted a challenge with syngeneic melanoma cells in contrast to animals without vitiligo. Our results confirm that vitiligo is associated with clinical benefit and further demonstrate the crucial role of CD8+ T cells for tumor control in melanoma-associated vitiligo.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14973052     DOI: 10.1158/0008-5472.can-03-2828

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  20 in total

Review 1.  Immune predictors of cancer progression.

Authors:  Benjamin Toh; Valerie Chew; Xilei Dai; Karen Khoo; Muly Tham; Lu-En Wai; Sandra Hubert; Sumathy Velumani; Liang Zhi; Caleb Huang; Jean-Pierre Abastado
Journal:  Immunol Res       Date:  2012-09       Impact factor: 2.829

2.  IL4-induced gene 1 promotes tumor growth by shaping the immune microenvironment in melanoma.

Authors:  Lloyd Bod; Renée Lengagne; Ludovic Wrobel; Jan Philipp Ramspott; Masashi Kato; Marie-Françoise Avril; Flavia Castellano; Valérie Molinier-Frenkel; Armelle Prévost-Blondel
Journal:  Oncoimmunology       Date:  2017-01-13       Impact factor: 8.110

3.  Tumor stroma and chemokines control T-cell migration into melanoma following Temozolomide treatment.

Authors:  Kar Wai Tan; Maximilien Evrard; Muly Tham; Michelle Hong; Caleb Huang; Masashi Kato; Armelle Prevost-Blondel; Emmanuel Donnadieu; Lai Guan Ng; Jean-Pierre Abastado
Journal:  Oncoimmunology       Date:  2015-02-25       Impact factor: 8.110

4.  Advanced malignant melanoma responds to Prunus mume Sieb. Et Zucc (Ume) extract: Case report and in vitro study.

Authors:  Shigeto Matsushita; Ko-Ichi Tada; Ko-Ichi Kawahara; Kazuhiro Kawai; Teruto Hashiguchi; Ikuro Maruyama; Takuro Kanekura
Journal:  Exp Ther Med       Date:  2010-07-01       Impact factor: 2.447

5.  Autoimmune melanocyte destruction is required for robust CD8+ memory T cell responses to mouse melanoma.

Authors:  Katelyn T Byrne; Anik L Côté; Peisheng Zhang; Shannon M Steinberg; Yanxia Guo; Rameeza Allie; Weijun Zhang; Marc S Ernstoff; Edward J Usherwood; Mary Jo Turk
Journal:  J Clin Invest       Date:  2011-04-11       Impact factor: 14.808

6.  Nitric oxide synthase 2 is involved in the pro-tumorigenic potential of γδ17 T cells in melanoma.

Authors:  Laetitia Douguet; Lloyd Bod; Renée Lengagne; Laura Labarthe; Masashi Kato; Marie-Françoise Avril; Armelle Prévost-Blondel
Journal:  Oncoimmunology       Date:  2016-08-10       Impact factor: 8.110

7.  Tumor microenvironment and myeloid-derived suppressor cells.

Authors:  Viktor Umansky; Alexandra Sevko
Journal:  Cancer Microenviron       Date:  2012-12-16

8.  Targeting surface nucleolin with a multivalent pseudopeptide delays development of spontaneous melanoma in RET transgenic mice.

Authors:  Diala El Khoury; Damien Destouches; Renée Lengagne; Bernard Krust; Yamina Hamma-Kourbali; Marylène Garcette; Sandra Niro; Masashi Kato; Jean-Paul Briand; José Courty; Ara G Hovanessian; Armelle Prévost-Blondel
Journal:  BMC Cancer       Date:  2010-06-24       Impact factor: 4.430

9.  Inflammatory monocytes are potent antitumor effectors controlled by regulatory CD4+ T cells.

Authors:  Arnaud Pommier; Alexandra Audemard; Aurélie Durand; Renée Lengagne; Arnaud Delpoux; Bruno Martin; Laetitia Douguet; Armelle Le Campion; Masashi Kato; Marie-Françoise Avril; Cédric Auffray; Bruno Lucas; Armelle Prévost-Blondel
Journal:  Proc Natl Acad Sci U S A       Date:  2013-07-22       Impact factor: 11.205

10.  NCRs and DNAM-1 mediate NK cell recognition and lysis of human and mouse melanoma cell lines in vitro and in vivo.

Authors:  Tadepally Lakshmikanth; Shannon Burke; Talib Hassan Ali; Silvia Kimpfler; Francesco Ursini; Loredana Ruggeri; Marusca Capanni; Viktor Umansky; Annette Paschen; Antje Sucker; Daniela Pende; Veronika Groh; Roberto Biassoni; Petter Höglund; Masashi Kato; Kazuko Shibuya; Dirk Schadendorf; Andrea Anichini; Soldano Ferrone; Andrea Velardi; Klas Kärre; Akira Shibuya; Ennio Carbone; Francesco Colucci
Journal:  J Clin Invest       Date:  2009-04-06       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.